Parasutterella excrementihominis Drives a Pro-Inflammatory Loop in Colitis and Colitis-Associated Cancer
Parasutterella excrementihominis is emerging as more than a passive bystander in ulcerative colitis. In work published in Gut, investigators linked enrichment of this Betaproteobacteria species to worsened experimental colitis and colitis-associated colorectal cancer, tracing its effects to a metabolite-driven pathway that activates neutrophil extracellular trap formation, or NETosis.
The clinical signal began in human stool samples. Patients with ulcerative colitis carried higher levels of P. excrementihominis than healthy controls, placing the organism in the same microbial setting as a chronically inflamed colon already primed for epithelial injury, neutrophil influx, and mucosal barrier breakdown. From there, the mechanistic work moved into murine DSS colitis and azoxymethane/DSS cancer models, where the bacterium aggravated both inflammatory injury and tumor development.
The biology is not subtle. A bacterium associated with ulcerative colitis was shown to intensify the very immune machinery that can push inflamed tissue toward neoplasia.
Neutrophils, NETs, and the Shift From Inflammation to Tumor Promotion
The central pathogenic thread ran through neutrophils. P. excrementihominis expanded colonic neutrophils and increased NET formation, creating a pro-inflammatory environment with direct relevance to tissue damage and cancer biology. NETs are web-like structures released by activated neutrophils, classically meant to trap microbes, but in chronic intestinal inflammation they can damage epithelium, amplify oxidative stress, and feed a microenvironment that supports tumor initiation and progression.
In the cancer model, those effects did not remain confined to inflammation alone. The bacterium exacerbated colitis-associated colorectal cancer, consistent with a pathologic sequence in which repeated injury, innate immune activation, and persistent mucosal repair responses converge on malignant transformation. In the setting of colitis, a neutrophil program that is useful in acute infection can become maladaptive when it stays switched on.
The study’s mechanistic strength came from connecting the organism to a defined host effector pathway rather than stopping at association. Neutrophil-specific deletion of gasdermin D, the pore-forming protein needed for this form of cellular execution, attenuated metabolite-driven tumorigenesis. That result places GSDMD-dependent NETosis near the center of the bacterial effect, not as a peripheral consequence of inflammation.
Succinate and 6-Hydroxyhexanoic Acid Link Bacterial Metabolism to Host Injury
Metabolomic profiling provided the most granular explanation for how P. excrementihominis exerts its effects. The bacterium increased the host’s carbohydrate metabolic capacity and led to higher production of succinic acid and 6-hydroxyhexanoic acid. Those metabolites were not merely biochemical curiosities. They activated GSDMD-dependent NETosis in lipopolysaccharide-primed neutrophils through the succinate receptor 1/G protein-coupled receptor 84 signaling axis.
This is the kind of pathway that makes translational sense at the bedside. Succinate is already recognized as a metabolic stress signal with immune effects, and in an inflamed colon it can behave like an alarm metabolite, strengthening neutrophil activation and helping sustain the feed-forward loop between microbial dysbiosis and mucosal injury. GPCR84, also known as SUCNR1 in some contexts, gives that metabolite a receptor-based route into immune activation, while GSDMD provides the cellular machinery for NETosis.
The result is a clear mechanistic bridge: microbial enrichment, altered metabolite output, neutrophil activation, extracellular trap release, and cancer promotion. Each step reinforces the next.
Why the Findings Matter for Ulcerative Colitis and CAC Biology
Colitis-associated colorectal cancer develops in a biologic setting defined by persistent inflammation, repeated epithelial damage, and immune dysregulation. The new data place P. excrementihominis inside that process as a microbial driver rather than a passive marker of disease severity. In practical terms, the organism may help explain why some inflamed colons remain stuck in a state of ongoing neutrophil recruitment and why that inflammatory pressure can translate into neoplastic risk over time.
The work also sharpens the role of NETosis in intestinal disease. NETs are often discussed as host-defense structures, but in chronic colitis they can become harmful scaffolds that sustain cytokine release, tissue destruction, and local oxidative injury. By showing that bacterial metabolites can directly trigger this pathway, the study moves the discussion from broad dysbiosis toward a more actionable microbial-metabolic-immune axis.
In the experimental setting, neutrophil-specific GSDMD deletion reduced the tumor-promoting impact of the bacterial metabolites, making GSDMD-dependent NETosis a plausible therapeutic node. Blocking the bacterium itself, dampening succinate-linked signaling, or limiting gasdermin-mediated trap formation could each interrupt a different step in the same inflammatory chain.
Clinical Implications and Remaining Translational Questions
For gastroenterology and oncology, the most relevant message is that a single microbial species may help coordinate inflammation and carcinogenesis through measurable metabolic products. If P. excrementihominis continues to show the same pattern in larger human datasets, stool-based microbial profiling could eventually contribute to risk stratification in ulcerative colitis, especially in patients with longstanding disease or recurrent severe inflammation.
The present findings remain preclinical in their mechanistic core. The human data establish enrichment in ulcerative colitis stool samples, but the cancer-promoting pathway was defined in animal models and cellular experiments. Human causal inference will require validation across larger cohorts, longitudinal sampling, and direct correlation with dysplasia or colorectal cancer outcomes.
Even so, the biologic logic is unusually coherent. A bacterium enriched in ulcerative colitis increases succinate and 6-hydroxyhexanoic acid, activates neutrophil gasdermin D pathways, intensifies NETosis, and worsens both colitis and colitis-associated colorectal cancer. That sequence provides a concrete target list for future intervention studies, and it narrows the field from general inflammation to a defined microbial-metabolic circuit that can now be tested in patients.
- • PubMed PMID 41448880: https://pubmed.ncbi.nlm.nih.gov/41448880/